NeuroX1 is developing a target ID and drug discovery platform leveraging proprietary generative AI algorithms to create the next generation of therapeutics for neurological disorders. Our early-stage pipeline consists of several pre-clinical assets partnered with a variety of pharma companies and institutions.
There are few options for the treatment of neurological and neurodegenerative diseases. The market for neurodegenerative diseases is roughly $52B, while the market for neurological diseases is roughly$ 82B. The market for brain cancer, a traditionally tricky cancer to treat and one that is also applicable to our platform, is several billion as well. If you include all neurological disorders, including rare/orphan diseases, the market is $125.3B by 2030.
